$Prominent ‘Y’ descent is an ominous sign of a poorer prognosis in heart failure with preserved ejection fraction$

Prominent ‘Y’ descent is an ominous sign of a poorer prognosis in heart failure with preserved ejection fraction

Abstract Aims The heterogeneity of heart failure with preserved ejection fraction (HFpEF) represents different pathophysiological paths by which individual patients develop heart failure. The deterioration mechanisms are considered to be mainly left ventricular diastolic dysfunction, right ventricul...

Full description

Bibliographic Details
Main Authors:	Daisuke Harada, Hidetsugu Asanoi, Takahisa Noto, Junya Takagawa
Format:	Article
Language:	English
Published:	Wiley 2019-08-01
Series:	ESC Heart Failure
Subjects:	HFpEF Heart failure Right ventricular distensibility Jugular venous pulse Right ventricular systolic pressure Right ventricular dysfunction
Online Access:	https://doi.org/10.1002/ehf2.12460

Similar Items

Different Pathophysiology and Outcomes of Heart Failure With Preserved Ejection Fraction Stratified by K-Means Clustering
by: Daisuke Harada, et al.
Published: (2020-11-01)

Fibrosis‐4 index reflects right ventricular function and prognosis in heart failure with preserved ejection fraction
by: Mitsutaka Nakashima, et al.
Published: (2021-06-01)

Impact of severe obesity on exercise performance in heart failure with preserved ejection fraction
by: Satyam Sarma, et al.
Published: (2020-11-01)

Approach to the Treatment of Heart Failure With Preserved Ejection Fraction and Mid-Range Ejection Fraction
by: Ewa A Jankowska, et al.
Published: (2017-01-01)

Prognostic significance of the HFA‐PEFF score in patients with heart failure with preserved ejection fraction
by: Yohei Sotomi, et al.
Published: (2021-06-01)

Murine Models of Heart Failure With Preserved Ejection Fraction
by: Maria Valero-Muñoz, PhD, et al.
Published: (2017-12-01)

Optimizing the discovery and assessment of therapeutic targets in heart failure with preserved ejection fraction
by: Gabrielle Fusco‐Allison, et al.
Published: (2021-10-01)

Reduction of Pulmonary Hypertension After Transition to Sacubitril/Valsartan in Patients With Heart Failure With Preserved Ejection Fraction
by: Christof Burgdorf, et al.
Published: (2021-10-01)

Heart Failure: The Dilemma of the 40-50% Ejection Fraction Range
by: Michael Henein, et al.
Published: (2017-01-01)

Prognostic relevance of elevated plasma osmolality on admission in acute decompensated heart failure with preserved ejection fraction: insights from PURSUIT-HFpEF registry
by: Akito Nakagawa, et al.
Published: (2021-06-01)

Prevalence and prognostic value of various types of right ventricular dysfunction in mechanically ventilated septic patients
by: Hongmin Zhang, et al.
Published: (2021-07-01)

Multimodality assessment of heart failure with preserved ejection fraction skeletal muscle reveals differences in the machinery of energy fuel metabolism
by: Payman Zamani, et al.
Published: (2021-08-01)

Cardiac strain in right ventricular myocardial infarction and pulmonary embolism
by: E. S. Mazur, et al.
Published: (2020-03-01)

Stratified Treatment of Heart Failure with preserved Ejection Fraction: rationale and design of the STADIA‐HFpEF trial
by: Mariëlle Scheffer, et al.
Published: (2020-12-01)

Prognostic Significance of Right Ventricular Ejection Fraction Assessed by Two-Dimensional Echocardiography in Hospitalized Patients with Dilated Cardiomyopathy
by: G. Ravi Kiran, et al.
Published: (2019-01-01)

Hydrogen Sulfide as a Potential Therapy for Heart Failure—Past, Present, and Future
by: Kyle B. LaPenna, et al.
Published: (2021-03-01)

Leucocyte count predicts cardiovascular risk in heart failure with preserved ejection fraction: insights from TOPCAT Americas
by: Navkaranbir S. Bajaj, et al.
Published: (2020-08-01)

The controlling nutritional status score predicts outcomes of cardiovascular events in patients with heart failure with preserved ejection fraction
by: Takashi Komorita, et al.
Published: (2020-08-01)

Comparison of vectorcardiographic parameters with structural-functional state of the right ventricle in patients with pulmonary hypertension
by: E V Blinova, et al.
Published: (2015-12-01)

The Management of Heart Failure with Preserved Ejection Fraction (HFpEF)
by: Andrew J Stewart Coats, et al.
Published: (2014-01-01)

Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
by: Mark Sweeney, et al.
Published: (2020-10-01)

Sex and Heart Failure with Preserved Ejection Fraction: From Pathophysiology to Clinical Studies
by: Marijana Tadic, et al.
Published: (2019-06-01)

Heart Failure with Preserved Ejection Fraction (HFpEF): A Case Report
by: Amanda Halimi, et al.
Published: (2021-09-01)

Antiphospholipid Antibodies and Heart Failure with Preserved Ejection Fraction. The Multicenter ATHERO-APS Study
by: Daniele Pastori, et al.
Published: (2021-07-01)

Myths and Facts About Heart Failure with Preserved Ejection Fraction: Risk Factors, Longevity, Potential Pharmacological and Exercise Interventions
by: Chung-Lieh Hung, et al.
Published: (2013-03-01)

Large Animal Models of Heart Failure: Reduced vs. Preserved Ejection Fraction
by: Christopher J. Charles, et al.
Published: (2020-10-01)

Leukocyte count and the risk of adverse outcomes in patients with HFpEF
by: Zhaowei Zhu, et al.
Published: (2021-07-01)

Real‐world clinical diagnostics of heart failure patients with reduced or preserved ejection fraction
by: Jenni Huusko, et al.
Published: (2020-06-01)

Independent predictors of developing pulmonary hypertension in heart failure with reduced versus preserved ejection fraction
by: Alaa Roushdy, et al.
Published: (2017-07-01)

Growth differentiation factor 15 as mortality predictor in heart failure patients with non‐reduced ejection fraction
by: Ana Belen Mendez Fernandez, et al.
Published: (2020-10-01)

Effects of different exercise modalities on cardiac dysfunction in heart failure with preserved ejection fraction
by: David Bode, et al.
Published: (2021-06-01)

Clinical phenogroups are more effective than left ventricular ejection fraction categories in stratifying heart failure outcomes
by: Andreas B. Gevaert, et al.
Published: (2021-08-01)

Exosomal microRNAs miR-30d-5p and miR-126a-5p Are Associated with Heart Failure with Preserved Ejection Fraction in STZ-Induced Type 1 Diabetic Rats
by: Chang, C.-C, et al.
Published: (2022)

A composite metric for predicting benefit from spironolactone in heart failure with preserved ejection fraction
by: Mark N. Belkin, et al.
Published: (2021-10-01)

Variation in clinical and patient‐reported outcomes among complex heart failure with preserved ejection fraction phenotypes
by: Kelsey M. Flint, et al.
Published: (2020-06-01)

Plasma trimethylamine n-oxide is associated with renal function in patients with heart failure with preserved ejection fraction
by: Fei Guo, et al.
Published: (2020-08-01)

The role of vascular endothelial growth factor in heart failure with preserved ejection fraction
by: Glazyrine, Vassili
Published: (2016)

Heart Failure With Preserved Ejection Fraction and Obesity
by: Arjun Sinha, MD, et al.
Published: (2020-01-01)

Baseline characteristics of patients with heart failure and preserved ejection fraction at admission with acute heart failure in Saudi Arabia
by: Samah Abohammar, et al.
Published: (2017-03-01)

Inhalation of Ultrafine Zinc Particles Impaired Cardiovascular Functions in Hypertension-Induced Heart Failure Rats With Preserved Ejection Fraction
by: Fangbo Bing, et al.
Published: (2020-01-01)